Your session is about to expire
← Back to Search
Dendritic Cell Vaccine for Breast Cancer (DecipHER Trial)
DecipHER Trial Summary
This trial is testing whether an investigational vaccine can help people with certain types of breast cancer when given alongside standard chemotherapy drugs.
DecipHER Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowDecipHER Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.DecipHER Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have no cancer history except for certain skin cancers, cervical cancer in situ, or any cancer I've been free from for 3+ years.My tumor is either not hormone receptor positive or has low hormone receptor positivity.I have not received a live vaccine in the last 30 days.I have been treated with a therapy targeting HER2 or HER3 before.My breast cancer is in an early to mid-stage, with some lymph node involvement.I have received anthracycline-based chemotherapy before.I have an autoimmune disease that could come back or affects my organs.My doctor agrees I can have chemotherapy before surgery.I am not pregnant or nursing.I am 18 years old or older.I am using two forms of birth control and my pregnancy test was negative.I have tested positive for HIV/AIDS.I have not had breast cancer vaccine treatments in the last 3 months.I am fully active or can carry out light work.I have inflammatory breast cancer.My breast cancer is not HER2-positive.I am not currently on any experimental drugs or cancer treatments.I am using effective birth control and not pregnant if I can have children.I do not have any severe illnesses or mental health issues that would stop me from following the study's requirements.My breast cancer is in an early to mid-stage, with some lymph node involvement.My tumor is either not hormone receptor positive or has low hormone receptor positivity.My breast cancer is not HER2-positive.
- Group 1: Dendritic Cell Vaccine dose Escalation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still opportunities to volunteer for this study?
"The clinical trial is still in need of participants, as evidenced by the recent update posted on August 15th 2022. This study was initially publicized on 8/11/2022."
Has the FDA sanctioned using HER3 - primed Dendritic cells in treatments?
"This treatment has limited clinical data supporting both safety and efficacy, thus Power rated HER3 - primed Dendritic cells a 1 on the scale."
What is the full breadth of participants who are enrolled in this clinical research?
"That is correct. Clinicaltrials.gov has evidence that this clinical trial, first published on August 11th 2022, is still recruiting participants. 30 individuals are needed at just a single research site to complete the experiment."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger